Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02695537Phase 1Completed
Phase 1, open-label, single-arm trial of cannabidiol in epilepsy, sponsored by University of Alabama at Birmingham. Primary endpoints: Number of Participants With Severe Adverse Events at 1 year, Number of Participants With Change in Resting Blood Pressure or Heart Rate at 1 year and 1 more. Started Apr 2015; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02695537.